Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Evotec to expand compound management services to East Coast of US
The facility will be completely operational by the third quarter of 2013. The company’s South San Francisco facility will continue to carry out its operations to serve existing
The facility will be completely operational by the third quarter of 2013. The company’s South San Francisco facility will continue to carry out its operations to serve existing
Phase II trial being conducted by Novartis will assess INC280 as monotherapy in patients with advanced hepatocellular carcinoma. Under the terms of the deal signed between the companies,
Phase I trial is designed to assess bavituximab as combination therapy along with the chemotherapeutic agent paclitaxel in metastatic HER2-negative breast cancer patients. Bavituximab previously established tumor response
Through the deal, NutraGenesis gains exclusive rights to market Plandai’s patented Phytofare extracts in North America. Plandai marketing sales vice-president and global director Callum Baylis-Duffield said, "This is
The termination is attributed to delay in the expected regulatory approval and launch dates in countries where GSK holds commercialization rights. According to the terms of the deal
According to the deal, Merck, through a subsidiary, and Pfizer will work on the development and marketing of ertugliflozin and ertugliflozin-containing fixed-dose combinations with metformin and Januvia (sitagliptin)
As per the agreement, the Buyer, Bruce Perlowin, will purchase $50,000 of the protein each month for the duration of two years to total $1.2m for the company.
UMEC is an investigational bronchodilator molecule (formerly known as GSK573719), a long-acting muscarinic antagonist (LAMA), that is administered using the ELLIPTA inhaler. The MAA for UMEC monotherapy has
The most recent lawsuit alleges that the plaintiffs developed urinary and bladder issues, including bladder cancer, after they had consumed Actos and the drug is sold under the
FDA warned that Potiga may cause bluish skin predominantly around lips, fingers and toes and pigment changes in the retina, which may lead to loss of vision. GlaxoSmithKline